

Supporting Information for

New Cytotoxic Salinosporamides from the Marine Actinomycete *Salinispora tropica*.

Philip G. Williams, Greg O. Buchanan, Robert H. Feling, Christopher A. Kauffman,

Paul R. Jensen, William Fenical^{*}

Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography,

University of California-San Diego, La Jolla, California 92093-0204.

Table of Contents

Experimental Procedure	S4
Table S1. Spectral Data for Salinosporamide B (3).....	S7
Table S2. ^1H NMR Spectral Data for 5-9 at 300 MHz.....	S8
Table S3. ^{13}C NMR Spectral Data for 5-9 at 100 MHz.....	S9
Table S4. Spectral Data for 6 in CDCl_3	S10
Table S5. Spectral Data for 8 in C_6D_6	S11
Table S6. Spectral Data for 9 in C_6D_6	S12
Figure S1 ^1H NMR Spectrum (300 MHz) of Salinosporamide B (3) in pyridine- d_5	S13
Figure S2. ^{13}C NMR Spectrum (100 MHz) of Salinosporamide B (3) in pyridine- d_5	S14
Figure S3. COSY NMR Spectrum (300 MHz) of Salinosporamide B (3) in pyridine- d_5	S15
Figure S4. HSQC NMR Spectrum (300 MHz) of Salinosporamide B (4) in pyridine- d_5	S16
Figure S6. NOESY NMR Spectrum (300 MHz) of Salinosporamide B (4) in pyridine- d_5	S17
Figure S7. ^1H NMR Spectrum (300 MHz) of Salinosporamide C (4) in pyridine- d_5	S18
Figure S8. ^{13}C NMR Spectrum (100 MHz) of Salinosporamide C (4) in pyridine- d_5	S19
Figure S9. COSY NMR Spectrum (300 MHz) of Salinosporamide C (4) in pyridine- d_5	S20
Figure S10. HMQC NMR Spectrum (300 MHz) of Salinosporamide C (4) in pyridine- d_5	S21
Figure S11. HMBC NMR Spectrum (300 MHz) of Salinosporamide C (4) in pyridine- d_5	S22
Figure S12. NOESY NMR Spectrum (300 MHz) of 4 in pyridine- d_5	S23
Figure S13. ^1H NMR Spectrum (300 MHz) of 5 in pyridine- d_5	S24
Figure S14. ^{13}C NMR Spectrum (100 MHz) of 5 in pyridine- d_5	S25
Figure S15. ^1H NMR Spectrum (300 MHz) of 6 in pyridine- d_5	S26

Figure S16. ^{13}C NMR Spectrum (100 MHz) of 6 in pyridine- d_5	S27
Figure S17. ^1H NMR Spectrum (300 MHz) of 6 in CDCl_3	S28
Figure S18. ^{13}C NMR Spectrum (100 MHz) of 6 in CDCl_3	S29
Figure S19. COSY NMR Spectrum (300 MHz) of 6 in CDCl_3	S30
Figure S20. HQMC NMR Spectrum (300 MHz) of 6 in CDCl_3	S31
Figure S21. HMBC NMR Spectrum (300 MHz) of 6 in CDCl_3	S32
Figure S22. NOESY NMR Spectrum (300 MHz) of 6 in CDCl_3	S33
Figure S23. ^1H NMR Spectrum (300 MHz) of 7 in CDCl_3	S34
Figure S24. ^{13}C NMR Spectrum of (300 MHz) of 7 in CDCl_3	S35
Figure S25. ^1H NMR Spectrum (300 MHz) of 8 in benzene- d_6	S36
Figure S26. ^{13}C NMR Spectrum (100 MHz) of 8 in benzene- d_6	S37
Figure S27. HSQC NMR Spectrum (300 MHz) of 8 in benzene- d_6	S38
Figure S28. COSY NMR Spectrum (300 MHz) of 8 in benzene- d_6	S39
Figure S29. HMBC NMR Spectrum (300 MHz) of 8 in benzene- d_6	S40
Figure S30. NOESY NMR Spectrum (300 MHz) of 8 in benzene- d_6	S41
Figure S31. ^1H NMR Spectrum (300 MHz) of 9 in benzene- d_6	S42
Figure S32. ^{13}C NMR Spectrum (100 MHz) of 9 in benzene- d_6	S43
Figure S33. HSQC NMR Spectrum (300 MHz) of 9 in benzene- d_6	S44
Figure S34. COSY NMR Spectrum (300 MHz) of 9 in benzene- d_6	S45
Figure S35. HMBC NMR Spectrum (300 MHz) of 9 in benzene- d_6	S46
Figure S36. NOESY NMR Spectrum (300 MHz) of 9 in benzene- d_6	S47
Table S7. Results from Salinosporamide A NCI In-Vitro Testing.....	S48
Table S8. Results of Salinosporamide A in NCI 60-cell line panel – Mean Graphs.....	S49

General methods. Melting points were determined on a melting point block and are corrected. Optical rotations were measured at the sodium line (589 nm). IR bands were measured as a thin film on a NaCl disc. NMR spectra were acquired in C₆D₆ or C₅D₅N as indicated, while ¹³C NMR spectra were recorded on at 100 MHz using the residual solvent signals as an internal reference (C₆D₆, δ_H 7.16 ppm, δ_C 128.1 ppm; C₅D₅N, δ_H 7.22 ppm, δ_C 128.9 ppm). High-resolution mass spectral data were measured on a MALDI-FTMS using the ES mode.

Experimental Procedures

Cultivation of Strain CNB-392. Strain CNB-392 was isolated from a sample of sediment collected at a depth of approximately 1 m in June 1989 from a mangrove environment in Chub Cay, Bahamas. The strain was cultured in 2.8L Fernbach flasks (20 x 1L) in a seawater-based medium (chitosan 0.2%, kelp powder 0.2%, menhaden meal 0.2%, fish solubles 0.2%, starch 0.5%) and shaken at 230 rpm at 27 °C. After nine days of cultivation, 20 g of sterilized Amberlite XAD-16 resin was added to each flask and the slurry shaken for 24h.

Isolation of Compounds 5 and 6. XAD-16 resin was added to the 1L fermentations and the slurry left to shake for 24h before it was filtered off from the bacterial cells and washed with water. The resin was then extracted overnight with DCM-methanol (1:1) and the aqueous organic extract concentrated *in vacuo* to afford 349 mg of a dark brown gum. The gum was then subjected to purification by flash column chromatography using C-18 silica gel. Elution of the column with increasing concentrations of methanol in water gave nine fractions. The fractions eluting with 25 and 50% methanol in water were combined (115.6 mg) and subjected to further purification by normal phase HPLC using a mixture of hexane and ethyl acetate as the mobile phase.

Isolation of Compounds 1, 3, 4, 7-9. Strain CNB-392 was recultivated as described above, then the XAD-16 resin was then collected by filtration and washed with DI-water. After overnight extraction with a 1:1 mixture of DCM-acetone, the organic extract was concentrated *in vacuo* to afford 4.18 g of material. This material was then purified by silica flash column chromatography using increasing concentrations of acetone in dichloromethane. The fractions eluting with 10:1 and 5:1 DCM-acetone were combined and rotovaped to dryness. Recrystallization of this fraction from ethyl acetate-isooctane (3:1) afforded pure salinosporamide A (**1**, 150 mg, 3.6% yield based on the crude extract). Further purification by NP-HPLC [Dynamax, 250 x 10mm, flow rate 2.5 mL/min, RI detection] using a combination of hexane and ethyl acetate as the eluant yielded **1** and **3-9**.

Salinosporamide B (3, 6.3 mg, 0.15% yield): amorphous crystals, mp 143-145 °C; $[\alpha]_D$ -54.5° (*c* 0.286, MeOH); UV (MeOH) λ_{\max} (log ϵ) 256 (3.7) nm; IR (NaCl) ν_{\max} 3362, 2926, 1820, 1700 cm^{-1} ; ^1H and ^{13}C NMR see Table 1 and 2; ESIMS *m/z* 280.1 ($\text{M}+\text{H}$) $^+$; HRMALDI-FTMS *m/z* 279.1471 [calcd for $\text{C}_{15}\text{H}_{21}\text{NO}_4 \text{M}^+$, 279.1471].

Salinosporamide C (4, 6.0 mg, 0.14% yield): colorless oil, $[\alpha]_D$ -33.6° (*c* 0.268, MeOH); UV (MeOH) λ_{\max} (log ϵ) 222 (3.9) nm; IR (NaCl) ν_{\max} 3366, 2919, 1702, 1662, 1392, 1318, 1100 cm^{-1} ; ^1H and ^{13}C NMR see Table 2; ESIMS *m/z* 284.1 ($\text{M}+\text{H}$) $^+$; HRMALDI-FTMS *m/z* 284.1059 [calcd for $\text{C}_{14}\text{H}_{19}\text{ClNO}_3 (\text{M}+\text{H})^+$, 284.1053].

Compound 5 (4.4 mg): amorphous crystals, mp 158-160 °C, $[\alpha]_D$ -1.5° (*c* 1.0, MeOH); UV (MeOH) λ_{\max} (log ϵ) 256 (3.5), 204 (3.7) nm; IR (NaCl) ν_{\max} 3437, 3272, 2923, 2931, 1719, 1684, 1431, 1384, 1278, 1167, 1020 cm^{-1} ; ^1H and ^{13}C NMR see Table S1 and S2; ESIMS *m/z* 346.1 ($\text{M}+\text{H}$) $^+$; HRMALDI-FTMS *m/z* 346.1413 [calcd for $\text{C}_{16}\text{H}_{25}\text{ClNO}_5 (\text{M}+\text{H})^+$, 346.1421].

Compound 6 (6.0 mg): amorphous crystals, mp 180-181 °C, $[\alpha]_D$ -3.2° (*c* 1.0, MeOH); UV (MeOH) λ_{\max} (log ε) 256 (0.4), 208 (0.8) nm; IR (NaCl) ν_{\max} 3293, 2938, 1734, 1694, 1442, 1264, 1092 cm⁻¹; ¹H and ¹³C NMR see Table S1 and S2; ESIMS *m/z* 310.1 (M+H)⁺; HRMALDI-FTMS *m/z* 310.1637 [calcd for C₁₆H₂₄NO₅ (M+H)⁺, 310.1655].

Compound 7 (2.0 mg): colorless cubes, mp 144-145 °C, $[\alpha]_D$ -131.7° (*c* 0.315, MeOH); UV (MeOH) λ_{\max} (log ε) 282 (4.4) nm; IR (NaCl) ν_{\max} 3166, 3025, 2860, 1684 cm⁻¹; ¹H and ¹³C NMR see Table S1 and S2; ESIMS *m/z* 251.1 (M)⁺; HRMALDI-FTMS *m/z* 252.1147 [calcd for C₁₄H₁₉ClNO (M+H)⁺, 251.1155].

Compound 8 (2.9 mg): colorless oil, $[\alpha]_D$ -50.3° (*c* 0.165, MeOH); UV (MeOH) λ_{\max} (log ε) 234 (3.5) nm; IR (NaCl) ν_{\max} 3283, 2931, 2860, 1678, 1184, 1143, 1055 cm⁻¹; ¹H and ¹³C NMR see Table S1 and S2; ESIMS *m/z* 270.1 (M+H)⁺; HRMALDI-FTMS *m/z* 270.1271 [calcd for C₁₄H₂₁ClNO₂ (M+H)⁺, 270.1261].

Compound 9 (2.6 mg): colorless oil, $[\alpha]_D$ -8.8° (*c* 0.295, MeOH); UV (MeOH) λ_{\max} (log ε) 219 (4.4) nm; IR (NaCl) ν_{\max} 3319, 2923, 2849, 1672 cm⁻¹; ¹H and ¹³C NMR see Table S1 and S2; ESIMS *m/z* 270.1 (M+H)⁺; HRMALDI-FTMS *m/z* 270.1253 [calcd for C₁₄H₂₁ClNO₂ (M+H)⁺, 270.1260].

Table S1. Spectral Data for Salinosporamide B (**3**).

C/H#	3 δ _H ^a multiplicity (J in Hz)	3 δ _C ^b	COSY
1		176.9, C	
2	2.72, dd (8.8, 5.8)	49.8, CH	12a, 12b
3		86.3, C	
4		79.3, C	
5	4.24, t (8.8)	70.4, CH	5, OH
6	2.90, m	38.7, CH	5, 7, 11a, 11b
7	6.44, d (10.3)	128.2, CH	6, 8
8	5.88, m	128.4, CH	7, 9
9	1.92, m	24.7, CH ₂	8, 10
10a	1.39, m	21.1, CH ₂	9, 10b, 11a, 11b
10b	1.72, m		10a
11a	1.72, m	25.9, CH ₂	
11b	2.32, m		10a, 12a, 12b
12a	1.90, m	18.5, CH ₂	12b, 13a, 13b
12b	2.14, m		12a
13a	1.21, t (7.3)	12.3, CH ₂	12a, 12b, 13b
14	2.05, s	20.2, CH ₃	
15		169.1, C	
NH	10.42, br s		
OH	7.49, d (8.8)		

Table S2. ^1H NMR Spectral Data for **5-9** at 300 MHz.

H# ^a	5 ^b	6 ^b	7 ^c	8 ^c	9 ^c
1					
2	3.65, dd (8.8, 4.4)	3.29, d (7.3)			
3					
4			3.70, br s	3.70, d (5.2)	
5	4.54, d (6.4)	4.31, s	4.89, d (9.2)	3.27, d (10.0)	3.28, t (4.4)
6	2.71, m	2.72, m	2.95, m	2.42, m	2.16, m
7	6.50, d (10.7)	6.46, d (10.3)	5.66, m	6.22, d (10.4)	5.66, dd (10.4, 2.4)
8	5.78, br d (10.7)	5.78, br d (10.3)	5.48, d (9.2)	5.81, dm (10.4)	5.76, dq (10.4, 3.2)
9	1.93, m	1.93, m	1.83, m	1.94, m	1.78, m
10a	1.33, m	1.22, m	1.55-1.70, m	1.63, m	1.24, m
10b	1.68, m	1.62, m		1.73, m	
11a	1.62, m	1.83, m	1.55-1.70, m	1.71, m	1.30, m
11b	1.87, m			1.74, m	2.07, m
12a	2.39, m	2.49, m	2.50, t (6.9)	2.54, m	2.41, m
12b	2.65, m	2.69, m		2.64, m	2.51, m
13	4.18, t (7.3)	3.80, m	3.53, t (6.8)	3.60, m	3.60, m
		3.87, m		3.73, m	
14	2.10, s	1.65, s	1.50, s	1.55, s	1.58, s
15					
16	3.69, s	3.79, s			
NH	9.80, br s	9.98, br s		8.55, br s	7.23, br s
OH	6.85, br s	6.85, br s			

^a Numbering consistent with Salinosporamide A (**1**). ^b NMR spectra recorded in $\text{C}_5\text{D}_5\text{N}$.

^c NMR spectra recorded in C_6D_6 .

Table S3. ^{13}C NMR Spectral Data for **5-9** at 100 MHz.

Carbon # ^a	5 ^b	6 ^b	7 ^c	8 ^c	9 ^c
C-1	178.6, C	177.8, C	171.6, C	176.3, C	173.9, C
C-2	49.6, CH	53.6, CH	128.4, C	129.6, C	130.0, C
C-3	82.1, C	91.0, C	143.3, C	155.7, C	154.6, C
C-4	78.1, C	76.4, C	138.2, C	63.2, CH	63.0, CH
C-5	77.0, CH	76.3, CH	114.7, CH	73.8, CH	76.0, CH
C-6	40.5, CH	39.5, CH	38.4, CH	40.9, CH	38.4, CH
C-7	129.1, CH	128.8, CH	129.1, CH	129.1, CH	131.2, CH
C-8	129.2, CH	129.4, CH	127.3, CH	128.2, CH	126.6, CH
C-9	25.6, CH ₂	25.6, CH ₂	25.2, CH ₂	25.6, CH ₂	25.5, CH ₂
C-10	22.6, CH ₂	22.5, CH ₂	21.3, CH ₂	22.2, CH ₂	22.0, CH ₂
C-11	27.4, CH ₂	26.7, CH ₂	29.7, CH ₂	26.7, CH ₂	27.5, CH ₂
C-12	29.5, CH ₂	28.7, CH ₂	27.8, CH ₂	27.7, CH ₂	27.7, CH ₂
C-13	45.4, CH ₂	67.4, CH ₂	43.2, CH ₂	43.4, CH ₂	43.5, CH ₂
C-14	21.3, CH ₃	20.4, CH ₃	9.6, CH ₃	12.4, CH ₃	13.6, CH ₃
C-15	172.2, C	171.5, C			
C-16	51.8, CH ₃	52.0, CH ₃			

^a Numbering consistent with Salinosporamide A (**1**). ^b NMR spectra recorded in $\text{C}_5\text{D}_5\text{N}$.

^c NMR spectra recorded in C_6D_6 .

Table S4. Spectral Data for **6** in CDCl₃.

C/H #	δ _H multiplicity (<i>J</i> in Hz)	δ _C	COSY	HMBC	ROESY
1		177.3, C			
2	2.91, d (8.0)	52.4, CH	12b	1, 3, 12, 13	12a, 12b, 14
3		89.9, C			
4		52.4, C			
5	4.00, br s	75.2, CH	6	4, 7, 15	14
6	2.20, m	38.2, CH	5		
7	5.61, br d (9.0)	123.7, CH		5, 6, 8, 9, 11	
8	6.02, br d (10.0)	134.4, CH			6, 7, 9, 10
9a	1.75, m	28.3, CH ₂			
9b	1.50, m				
10	1.60, m	20.8, CH ₂			
11	1.98, m	25.0, CH ₂			
12a	2.35, dd (12.5, 5.0)	28.0, CH ₂	12b, 13a, 13b		
12b	2.00, m		12a, 13a, 13b		
13a	3.90, td (8.5, 1.5)	67.2, CH ₂	13b		
13b	3.70, m		13a		
14	1.55, s	19.8, CH ₃		2, 3, 4	2, 5, 13a
15		169.7, C			
16	3.79, s	52.5, CH ₃	15		

Table S5. Spectral Data for **8** in C₆D₆.

C/H #	δ_{H} multiplicity (J in Hz)	δ_{c}	COSY	HMBC	ROESY
1		176.3, C			
2		129.6, C			
3		155.7, C			
4	3.70, br s	63.2, CH	5, 6, NH	1, 2, 3	4, 5, 10b, 12b, NH
5	3.27, d (10.0)	73.8, CH	4, 6		
6	2.42, m	40.9, CH	5, 10		7, 10b, NH
7	6.22, d (10.4)	129.1, CH	6, 8, 9		6, 8
8	5.81, dm (10.4)	128.2, CH	7, 9		7, 9
9	1.94, m	25.6, CH ₂	6, 8		8, 10b
10a	1.63, m	22.2, CH ₂	9, 10		
10b	1.73, m		6, 10		4, 5, 6
11a	1.71, m	26.7, CH ₂			
11a	1.74, m		6, 10		4, 5, 6
12a	2.54, m	27.7, CH ₂	13	1, 2, 3, 13	12b
12b	2.64, m		13	1, 2, 3, 13	12a
13a	3.60, m	43.4, CH ₂	12, 13	2, 12	12b, 13b
13b	3.73, m		12, 13	2, 12	12b, 13a
14	1.55, s	12.4, CH ₃		1, 2, 3, 4, 13	4, 5, 12b
NH	8.55, br s		4	3, 4, 7	4, 6

Table S6. Spectral Data for **9** in C₆D₆.

C/H #	δ_{H} multiplicity (J in Hz)	δ_{c}	COSY	HMBC	ROESY
1		173.9, C			
2		130.0, C			
3		154.6, C			
4	3.70, d (5.2)	63.0, CH		2, 3, 5, 6	NH, 8, 7, 5, 14
5	3.28, t (4.4)	76.0, CH	4, 6	2, 6, 8	4, 6, 14
6	2.16, m	38.4, CH	5		NH, 8, 7, 5, 10
7	5.66, dd (10.4, 2.4)	131.2, CH		9	4, 8, 6, 9
8	5.76, dq (10.4, 3.2)	126.6, CH	9	6	6, 7, 6, 9
9	1.78, m	25.5, CH ₂	8		7, 10
10a	1.24, m	22.0, CH ₂	6		
10b	1.30, m				
11	2.07, m	27.5, CH ₂			
12a	2.41, m	27.7, CH ₂	13	1, 2, 3, 13	
12b	2.51, m		13	1, 2, 3, 13	
13	3.60, m	43.5, CH ₂		2	12a, 12b
14	1.58, s	13.6, CH ₃		1, 2, 3, 4, 13	4, 5
NH	7.23, br s				4, 6

Figure S1. ^1H NMR Spectrum (300 MHz) of Salinosporamide B (**3**) in pyridine- d_5




Figure S2. ^{13}C NMR Spectrum (100 MHz) of Salinosporamide B (**3**) in pyridine- d_5




Figure S3. COSY NMR Spectrum (300 MHz) of Salinosporamide B (**3**) in pyridine-*d*₅




Figure S4. HSQC NMR Spectrum (300 MHz) of Salinosporamide B (**3**)in pyridine-*d*₅




Figure S6. NOESY NMR Spectrum (300 MHz) of Salinosporamide B (**3**) in pyridine-*d*₅




Figure S7. ^1H NMR Spectrum (300 MHz) of Salinosporamide C (**4**) in pyridine- d_5




Figure S8. ^{13}C NMR Spectrum (100 MHz) of Salinosporamide C (**4**) in pyridine- d_5




Figure S9. COSY NMR Spectrum (300 MHz) of Salinosporamide C (**4**) in pyridine-*d*₅




Figure S10. HMQC NMR Spectrum (300 MHz) of Salinosporamide C (**4**) in pyridine-*d*₅




Figure S11. HMBC NMR Spectrum (300 MHz) of Salinosporamide C (**4**) in pyridine-*d*₅




Figure S12. NOESY NMR Spectrum (300 MHz) of Salinosporamide C (**4**) in pyridine-*d*₅




Figure S13. ^1H NMR Spectrum (300 MHz) of **5** in pyridine- d_5





Figure S14. ^{13}C NMR Spectrum (100 MHz) of **5** in pyridine- d_5




Figure S15. ^1H NMR Spectrum (300 MHz) of **6** in pyridine- d_5




Figure S16. ^{13}C NMR Spectrum (100 MHz) of **6** in pyridine- d_5




Figure S17. ^1H NMR Spectrum (300 MHz) of **6** in CDCl_3




Figure S18. ^{13}C NMR Spectrum (100 MHz) of **6** in CDCl_3




Figure S19. HMQC NMR Spectrum (300 MHz) of **6** in CDCl_3




Figure S20. COSY NMR Spectrum (300 MHz) of **6** in CDCl_3





Figure S21. HMBC NMR Spectrum (300 MHz) of **6** in CDCl_3






Figure S22. NOESY NMR Spectrum (300 MHz) of **6** in CDCl_3




Figure S23. ^{13}H NMR Spectrum (300 MHz) of **7** in CDCl_3




Figure S24. ^{13}C NMR Spectrum (100 MHz) of **7** in CDCl_3




Figure S25. ^1H NMR Spectrum (300 MHz) of **8** in benzene- d_6




Figure S26. ^{13}C NMR Spectrum (100 MHz) of **8** in benzene- d_6




Figure S27. .HSQC NMR Spectrum (300 MHz) of **8** in benzene-*d*₆




Figure S28. COSY NMR Spectrum (300 MHz) of **8** in benzene-*d*₆




Figure S29. HMBC NMR Spectrum (300 MHz) of **8** in benzene-*d*₆




Figure S30. NOESY NMR Spectrum (300 MHz) of **8** in benzene-*d*₆




Figure S31. ^1H NMR Spectrum (300 MHz) of **9** in benzene- d_6




Figure S32. ^{13}C NMR Spectrum (100 MHz) of **9** in benzene- d_6




Figure S33. .HSQC NMR Spectrum (300 MHz) of **9** in benzene-*d*₆




Figure S34. COSY NMR Spectrum (300 MHz) of **9** in benzene-*d*₆




Figure 35. HMBC NMR Spectrum (300 MHz) of **9** in benzene-*d*₆




Figure S36. .NOESY NMR Spectrum (300 MHz) of **9** in benzene-*d*₆




Table S7. Results from Salinosporamide A NCI In-Vitro Testing

National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results																
NSC: D-721267 / 1				Experiment ID: 0106NS98-75								Test Type: 08		Units: Molar		
Report Date: August 1, 2001				Test Date: June 25, 2001								QNS:		MC:		
COMI: CNB932.313 (8348)				Stain Reagent: SRB Dual-Pass								SSPL: 075T				
Log10 Concentration																
Panel/Cell Line	Time	Zero	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0	GI50	TGI	LC50
Leukemia																
CCRF-CEM	0.119	0.656	0.205	0.228	0.207	0.195	0.208	16	20	16	14	16	<1.00E-08	>1.00E-04	>1.00E-04	
HL-60(TB)	0.902	1.969	1.009	1.040	0.930	0.985	0.924	10	13	3	8	2	<1.00E-08	>1.00E-04	>1.00E-04	
K-562	0.221	0.869	0.413	0.354	0.255	0.197	0.166	30	20	5	11	25	<1.00E-08	2.12E-06	>1.00E-04	
MOLT-4	0.138	0.657	0.424	0.399	0.169	0.189	0.178	55	50	6	10	8	1.01E-07	>1.00E-04	>1.00E-04	
REPMI-8226	0.395	1.013	0.325	0.323	0.306	0.304	0.318	-18	-18	-23	-23	-20	<1.00E-08	<1.00E-08	>1.00E-04	
SR	0.260	0.696	0.149	0.173	0.161	0.148	0.153	-43	-34	-38	-43	-41	<1.00E-08	<1.00E-08	>1.00E-04	
Non-Small Cell Lung Cancer																
A549/ATCC	0.203	1.051	0.467	0.426	0.340	0.210	0.108	31	26	16	1	-47	<1.00E-08	1.04E-05	>1.00E-04	
EKVX	0.483	1.026	0.688	0.601	0.548	0.497	0.545	38	22	12	2	11	<1.00E-08	>1.00E-04	>1.00E-04	
HOP-62	0.399	0.873	0.434	0.459	0.331	0.268	0.224	7	13	-17	-33	44	<1.00E-08	2.66E-07	>1.00E-04	
NCI-H226	0.789	1.012	0.457	0.452	0.481	0.395	0.280	-42	-43	-39	-50	-65	<1.00E-08	<1.00E-08	1.01E-05	
NCI-H23	0.268	0.627	0.217	0.182	0.104	0.089	0.096	-19	-32	-61	-67	-64	<1.00E-08	<1.00E-08	4.09E-07	
NCI-H322M	0.725	1.201	0.793	0.654	0.583	0.363	0.389	14	10	-20	-50	-46	<1.00E-08	3.89E-08	>1.00E-04	
NCI-H460	0.113	1.247	0.359	0.263	0.228	0.119	0.146	22	13	10	1	3	<1.00E-08	>1.00E-04	>1.00E-04	
NCI-H522	0.652	1.289	0.246	0.139	0.109	0.135	0.091	-62	-79	-83	-79	-86	<1.00E-08	<1.00E-08	<1.00E-08	
Colon Cancer																
COLO 205	0.415	1.401	0.622	0.559	0.401	0.196	0.084	21	15	-3	-53	-80	<1.00E-08	6.40E-07	8.74E-06	
HCC-2998	0.227	0.470	0.130	0.085	0.025	0.010	0.018	-43	-63	-89	-96	-92	<1.00E-08	<1.00E-08	2.33E-08	
HCT-116	0.088	0.513	0.096	0.088	0.038	0.014	0.016	2	-1	-57	-84	-82	<1.00E-08	5.71E-08	7.41E-07	
HCT-15	0.237	0.973	0.404	0.419	0.323	0.281	0.184	23	25	12	6	-22	<1.00E-08	1.63E-05	>1.00E-04	
KM12	0.415	1.266	0.512	0.495	0.337	0.301	0.358	11	9	-19	-27	-14	<1.00E-08	2.14E-07	>1.00E-04	
SW-620	0.266	0.955	0.353	0.309	0.272	0.243	0.214	13	6	1	-9	-20	<1.00E-08	1.21E-06	>1.00E-04	
CNS Cancer																
SF-268	0.293	1.040	0.451	0.407	0.427	0.308	0.261	21	15	18	2	-11	<1.00E-08	1.42E-05	>1.00E-04	
SF-295	0.376	1.131	0.298	0.208	0.093	0.042	0.101	-21	-45	-75	-89	-73	<1.00E-08	<1.00E-08	1.49E-07	
SF-539	0.814	1.619	0.702	0.660	0.534	0.540	0.522	-14	-19	-34	-34	-36	<1.00E-08	<1.00E-08	>1.00E-04	
SNB-19	0.463	0.934	0.517	0.488	0.474	0.475	0.413	11	5	2	3	-11	<1.00E-08	1.55E-05	>1.00E-04	
U251	0.304	1.252	0.299	0.283	0.268	0.148	0.081	-2	-7	-12	-51	-74	<1.00E-08	<1.00E-08	9.26E-06	
Melanoma																
LOX IMVI	0.202	0.976	0.158	0.131	0.046	0.020	0.019	-22	-35	-77	-90	-91	<1.00E-08	<1.00E-08	2.24E-07	
MALME-3M	0.810	1.376	0.683	0.750	0.675	0.615	0.815	-16	-7	-17	-24	1	<1.00E-08	>1.00E-04	>1.00E-04	
M14	0.186	0.544	0.238	0.205	0.140	0.095	0.137	14	5	-25	-49	-27	<1.00E-08	1.50E-07	>1.00E-04	
SK-MEL-2	0.853	1.733	0.333	0.354	0.198	0.209	0.159	61	-58	-77	-75	-81	<1.00E-08	<1.00E-08	<1.00E-08	
SK-MEL-28	0.717	0.985	0.321	0.296	0.310	0.289	0.210	-55	-59	-57	-60	-71	<1.00E-08	<1.00E-08	<1.00E-08	
SK-MEL-5	0.455	1.573	0.253	0.169	0.098	0.126	0.104	-44	-63	-78	-72	-77	<1.00E-08	<1.00E-08	2.01E-08	
UACC-257	0.342	1.203	0.308	0.428	0.225	0.341	0.365	-10	10	-34	-3	-3	<1.00E-08	>1.00E-04	>1.00E-04	
UACC-62	0.812	1.804	0.610	0.480	0.374	0.114	0.137	-25	-41	-54	-86	-83	<1.00E-08	<1.00E-08	4.94E-07	
Ovarian Cancer																
IGROV1	0.681	1.489	0.849	0.917	0.707	0.416	0.153	21	29	3	-39	-78	<1.00E-08	1.19E-06	1.93E-05	
OVCAR-3	0.510	1.427	0.583	0.601	0.418	0.280	0.271	8	10	-18	-45	-47	<1.00E-08	2.26E-07	>1.00E-04	
OVCAR-5	0.376	0.851	0.440	0.406	0.337	0.284	0.301	13	6	-10	-24	-20	<1.00E-08	2.37E-07	>1.00E-04	
OVCAR-8	0.200	1.075	0.387	0.322	0.174	0.172	0.108	21	14	-13	-14	-46	<1.00E-08	3.25E-07	>1.00E-04	
SK-OV-3	0.822	1.408	0.811	0.789	0.725	0.630	0.454	-1	-4	-12	-23	-45	<1.00E-08	<1.00E-08	>1.00E-04	
Renal Cancer																
786-O	0.353	0.958	0.431	0.427	0.340	0.215	0.138	13	12	-4	-39	-61	<1.00E-08	5.76E-07	3.12E-05	
A498	0.964	1.451	0.384	0.241	0.223	0.275	0.286	-60	-75	-77	-71	-70	<1.00E-08	<1.00E-08	<1.00E-08	
ACHN	0.295	1.059	0.418	0.408	0.345	0.280	0.131	16	15	7	-5	-56	<1.00E-08	3.65E-06	7.70E-05	
CAKI-1	0.566	1.847	0.664	0.638	0.545	0.456	0.315	8	6	-4	-19	-44	<1.00E-08	3.94E-07	>1.00E-04	
RF5 393	0.194	0.723	0.289	0.228	0.177	0.184	0.112	18	6	-9	-5	-43	<1.00E-08	2.59E-07	>1.00E-04	
SNUC2	0.368	0.975	0.363	0.290	0.230	0.072	0.055	-1	-21	-38	-81	-85	<1.00E-08	<1.00E-08	1.95E-06	
TK-10	0.428	0.961	0.515	0.490	0.370	0.324	0.350	16	12	-14	-24	-18	<1.00E-08	2.87E-07	>1.00E-04	
UO-31	0.416	1.227	0.732	0.679	0.449	0.324	0.127	39	32	4	-22	-70	<1.00E-08	1.42E-06	3.86E-05	
Prostate Cancer																
PC-3	0.288	0.648	0.362	0.351	0.287	0.248	0.207	20	18	-	-14	-28	<1.00E-08	9.56E-07	>1.00E-04	
DU-145	0.149	0.627	0.338	0.338	0.331	0.307	0.239	40	39	38	33	19	<1.00E-08	>1.00E-04	>1.00E-04	
Breast Cancer																
MCF7	0.099	1.137	0.550	0.502	0.420	0.199	0.299	43	39	31	29	19	<1.00E-08	>1.00E-04	>1.00E-04	
NCI/ADR-RES	0.658	1.347	0.673	0.600	0.573	0.604	0.389	2	-9	-13	-8	-41	<1.00E-08	1.57E-08	>1.00E-04	
MDA-MB 231/ATCC	0.441	0.903	0.397	0.344	0.300	0.254	0.198	-10	-22	-32	-43	-55	<1.00E-08	<1.00E-08	3.93E-05	
HS 578T	1.020	1.418	0.739	0.787	0.785	0.763	0.652	-28	-23	-25	-32	-32	<1.00E-08	<1.00E-08	>1.00E-04	
MDA-MB-435	0.465	1.621	0.159	0.177	0.131	0.080	0.091	-66	-62	-72	-83	-80	<1.00E-08			

Table S8. Results of Salinosporamide A in NCI 60-cell line panel.

